<! DOCTYPE = html>
<html>
<title>CS657 - Prescription</title>
<style>
div.container {
		width: 100%;
		border: 1px solid gray;
}

header{
		padding: 0.5em;
		#color: black;
		background-color: orange;
		clear: left;
		text-align: center;
}
.footer{
		padding : 1em;
		background-color: orange;
		text-align: center;
		<!--- position: fixed;>
		bottom : 0;
		width : 100%;
}

nav {
		float: left;
		max-width: 160px;
		margin: 0;
		padding: 1em;
}

nav ul {
		list-style-type: none;
		padding: 0;
}
	 
nav ul a {
		text-decoration: none;
}

article {
		margin-left: 170px;
		border-left: 1px solid gray;
		padding: 1em;
		overflow: hidden;
}
table {
		font-family: arial, sans-serif;
		border-collapse: collapse;
		width: 80%;
}

td, th {
		border: 4px solid #000000;
		text-align: middle;
		padding: 8px;
}

tr:nth-child(even) {
		background-color: #eeeeee;
}	

div.box {
		background-color: white;
		width: 300px;
		border: 2px solid green;
		padding: 10px;
		margin: 25px;
}
</style>
<body>
<div class="container">
	<header><h1>
		IIT Kanpur Medical Labs</h1>
	</header>
	<hr>	<h2> Precription for the query: </h2>
	<div class="box">
	back pain, fever, nausea, urinary incontinence, stress, urge
	</div>
	<hr>	<h2>
		Identified Disease: </h2>
	<div class="box">
	Postoperative Complications
	</div>
	<hr>	<h2>More Symptoms: </h2>
	<div class="box">
	Cyanosis, Heart Murmurs, Ataxia, Akathisia, Learning Disorders
	</div>
		<hr><h2>
Medication:</h2>
<table>
	<tr>
		<th>Serial No</th>
		<th>Drug Name</th>
		<th>Group</th>
		<th>Indication</th>
	</tr>	<tr>
		<td>1.</td>
		<td>Bromfenac</td>
		<td>Approved</td>
		<td>For the treatment of postoperative inflammation in patients who have undergone cataract extraction.</td>
	</tr>	<tr>
		<td>2.</td>
		<td>Coagulation factor VIIa Recombinant Human</td>
		<td>Approved</td>
		<td>For treatment of hemorrhagic complications in hemophilia A and B</td>
	</tr>	<tr>
		<td>3.</td>
		<td>Tinzaparin</td>
		<td>Approved</td>
		<td>Tinzaparin is used for the prevention of postoperative venous thromboembolism in patients undergoing orthopedic surgery and in patients undergoing general surgery who are at high risk of developing postoperative venous thromboembolism. It is also used for the treatment of deep vein thrombosis and/or pulmonary embolism. It is indicated for use in preventing clot formation in indwelling intravenous lines for hemodialysis.</td>
	</tr>	<tr>
		<td>4.</td>
		<td>Metreleptin</td>
		<td>Approved</td>
		<td>Metreleptin is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.</td>
	</tr>	<tr>
		<td>5.</td>
		<td>Bethanechol</td>
		<td>Approved</td>
		<td>For the treatment of acute postoperative and postpartum nonobstructive (functional) urinary retention and for neurogenic atony of the urinary bladder with retention.</td>
	</tr>	<tr>
		<td>6.</td>
		<td>Alizapride</td>
		<td>Approved</td>
		<td>Alizapride is used in the treatment of nausea and vomiting, including postoperative nausea and vomiting. </td>
	</tr>	<tr>
		<td>7.</td>
		<td>Dipyridamole</td>
		<td>Approved</td>
		<td>For as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement and also used in prevention of angina.</td>
	</tr>	<tr>
		<td>8.</td>
		<td>Alvimopan</td>
		<td>Approved, Investigational</td>
		<td>Used to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis. Also investigated for use in the treatment of pain (acute or chronic).</td>
	</tr>	<tr>
		<td>9.</td>
		<td>Betahistine</td>
		<td>Approved, Investigational</td>
		<td>For the reduction of episodes of vertigo association with Ménière's disease.</td>
	</tr>	<tr>
		<td>10.</td>
		<td>Dolasetron</td>
		<td>Approved, Investigational</td>
		<td>For the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including initial and repeat courses of chemotherapy. Also used for the prevention of postoperative nausea and vomiting. This drug can be used intravenously for the treatment of postoperative nausea and vomiting.</td>
	</tr>	<tr>
		<td>11.</td>
		<td>Piritramide</td>
		<td>Approved, Investigational</td>
		<td>Not Available</td>
	</tr>	<tr>
		<td>12.</td>
		<td>Diphenidol</td>
		<td>Approved, Investigational, Withdrawn</td>
		<td>For use in the prevention and symptomatic treatment of peripheral (labyrinthine) vertigo and associated nausea and vomiting that occur in such conditions as Meniere's disease and surgery of the middle and inner ear. Also for the control of nausea and vomiting associated with postoperative states, malignant neoplasms, labyrinthine disturbances, antineoplastic agent therapy, radiation sickness, and infectious diseases.</td>
	</tr>	<tr>
		<td>13.</td>
		<td>Ardeparin</td>
		<td>Approved, Investigational, Withdrawn</td>
		<td>For prevention of deep vein thrombosis, which may result in pulmonary embolism, following knee surgery.</td>
	</tr>	<tr>
		<td>14.</td>
		<td>Danegaptide</td>
		<td>Investigational</td>
		<td>Not Available</td>
	</tr>	<tr>
		<td>15.</td>
		<td>DG041</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in peripheral vascular disease.</td>
	</tr>	<tr>
		<td>16.</td>
		<td>Mosapride</td>
		<td>Investigational</td>
		<td>Not Available</td>
	</tr>	<tr>
		<td>17.</td>
		<td>Difelikefalin</td>
		<td>Investigational</td>
		<td>Not Available</td>
	</tr>	<tr>
		<td>18.</td>
		<td>Sonedenoson</td>
		<td>Investigational</td>
		<td>Not Available</td>
	</tr>	<tr>
		<td>19.</td>
		<td>MK-0686</td>
		<td>Investigational</td>
		<td>Not Available</td>
	</tr>	<tr>
		<td>20.</td>
		<td>Reglixane</td>
		<td>Investigational</td>
		<td>For the treatment of diabetes mellitus type 1 and 2.</td>
	</tr>	<tr>
		<td>21.</td>
		<td>OMS-103HP</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in inflammatory disorders (unspecified), knee replacement, orthopedic surgery, and pain (acute or chronic).</td>
	</tr>	<tr>
		<td>22.</td>
		<td>Caplacizumab</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in cardiovascular disorders and thrombosis.</td>
	</tr>	<tr>
		<td>23.</td>
		<td>BTA798</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in viral infection.</td>
	</tr>	<tr>
		<td>24.</td>
		<td>Ulimorelin</td>
		<td>Investigational</td>
		<td>Not Available</td>
	</tr>	<tr>
		<td>25.</td>
		<td>Tolrestat</td>
		<td>Withdrawn</td>
		<td>For the pharmacological control of certain diabetic complications.</td>
	</tr></table>
<div class="footer"> Copyright &copy : IIT Kanpur
</div>	
</div>
</body>
</html>